Thursday, 15 October 2026European Markets

AKER CARBON CAPTUR Stock Impressive Rise On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with AKER CARBON CAPTUR (ACC.OL) jumping 11.21% to kr14.98 on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI fell 0.22% to kr1,213.54, after four consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

AKER CARBON CAPTUR's last close was kr13.47, 46.76% under its 52-week high of kr25.30.

About AKER CARBON CAPTUR

Aker Carbon Capture ASA provides products, technology, and solutions within the field of carbon capture technologies, utilization, and storage in Norway and internationally. The company's carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. It offers carbon capture plants under the Just Catch and Big Catch brands. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Carbon Capture ASA is a subsidiary of Aker Horizons Holding AS.

Earnings Per Share

As for profitability, AKER CARBON CAPTUR has a trailing twelve months EPS of kr-0.33.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -20.91%.

Moving Average

AKER CARBON CAPTUR's value is way above its 50-day moving average of kr12.72 and above its 200-day moving average of kr14.16.

Volume

Today's last reported volume for AKER CARBON CAPTUR is 1145040 which is 20.85% above its average volume of 947461.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER CARBON CAPTUR's stock is considered to be oversold (<=20).

More news about AKER CARBON CAPTUR (ACC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com